Press coverage about AmerisourceBergen (NYSE:ABC) has trended somewhat positive on Saturday, according to Accern. Accern rates the sentiment of press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. AmerisourceBergen earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave news stories about the company an impact score of 45.0802249905089 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the media headlines that may have effected Accern Sentiment Analysis’s scoring:
- AmerisourceBergen (ABC) Now Covered by Analysts at Bank of America (americanbankingnews.com)
- The AmerisourceBergen Foundation Partners With Jefferson to Address Opioid Crisis (businesswire.com)
- Head to Head Review: AmerisourceBergen (ABC) and Its Peers (americanbankingnews.com)
- Patients can’t afford life-saving medications under new health plan change (finance.yahoo.com)
- AmerisourceBergen Corporation (ABC) expected to achieve earnings growth of -74.00% for this year – Wallstreet Investorplace (wallstreetinvestorplace.com)
A number of equities analysts recently weighed in on the stock. Mizuho set a $100.00 target price on shares of AmerisourceBergen and gave the stock a “hold” rating in a report on Wednesday, January 24th. Zacks Investment Research upgraded shares of AmerisourceBergen from a “hold” rating to a “buy” rating and set a $103.00 target price on the stock in a report on Thursday, February 8th. Cowen restated a “buy” rating and set a $108.00 target price on shares of AmerisourceBergen in a report on Tuesday, February 27th. Leerink Swann set a $105.00 target price on shares of AmerisourceBergen and gave the stock a “buy” rating in a report on Tuesday, January 2nd. Finally, Credit Suisse Group restated an “outperform” rating and set a $112.00 target price (up from $105.00) on shares of AmerisourceBergen in a report on Wednesday, February 7th. They noted that the move was a valuation call. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $103.34.
AmerisourceBergen (NYSE:ABC) last released its quarterly earnings data on Tuesday, February 6th. The company reported $1.55 EPS for the quarter, topping the Zacks’ consensus estimate of $1.35 by $0.20. AmerisourceBergen had a net margin of 0.66% and a return on equity of 53.65%. The firm had revenue of $40.47 billion during the quarter, compared to analysts’ expectations of $40.42 billion. During the same period in the previous year, the business posted $1.36 earnings per share. The company’s revenue for the quarter was up 6.0% compared to the same quarter last year. research analysts expect that AmerisourceBergen will post 6.58 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Monday, March 5th. Shareholders of record on Tuesday, February 20th were given a dividend of $0.38 per share. The ex-dividend date of this dividend was Friday, February 16th. This represents a $1.52 dividend on an annualized basis and a yield of 1.81%. AmerisourceBergen’s dividend payout ratio (DPR) is 32.76%.
In other AmerisourceBergen news, Director Richard W. Gochnauer sold 2,278 shares of AmerisourceBergen stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $101.13, for a total transaction of $230,374.14. Following the completion of the transaction, the director now directly owns 13,225 shares of the company’s stock, valued at $1,337,444.25. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Dale Danilewitz sold 3,121 shares of AmerisourceBergen stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $92.12, for a total transaction of $287,506.52. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 156,809 shares of company stock valued at $14,988,589. Company insiders own 27.30% of the company’s stock.
AmerisourceBergen Company Profile
AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, outsourced compounded sterile preparations, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and other alternate site pharmacies, and other customers.
Receive News & Ratings for AmerisourceBergen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AmerisourceBergen and related companies with MarketBeat.com's FREE daily email newsletter.